Pharm
Extended Spectrum Macrolide
search
Extended Spectrum Macrolide
, Azithromycin, Zithromax, Clarithromycin, Biaxin, Telithromycin, Ketek
See also
Erythromycin
Pharmacokinetics
Half Life
Clarithromycin: 5 hours
Telithromycin: 10 hours
Azithromycin: 68 hours
Precautions
Increasing
Macrolide
resistance for most indications (see below)
QT Prolongation
with Azithromycin (see below)
Calcium Channel Blocker
interaction with Clarithromycin (see below)
Macrolide
s in general (including Azithromycin) may increase heart defects with first trimester exposure of 5-7 days
Previously only Clarithromycin was considered a potential
Teratogen
(
Cleft Lip
association)
Fan (2020) BMJ 368: m331 +PMID:32075790 [PubMed]
Dosing
Azithromycin (Zithromax)
Directions
Take more than 1 hour before or 2 hours after food
Adult
Day 1: 500 mg PO qd
Day 2 to 5: 250 mg PO qd
Child
Day 1: 10 mg/kg PO qd (maximum: 500 mg)
Day 2 to 5: 5 mg/kg PO qd (maximum: 250 mg)
Infant under age 6 months
10 mg/kg/day for 5 days
New preparations
ZMax 2 grams orally x1 dose (Available in 2005)
For uncomplicated
Community Acquired Pneumonia
Vomiting
>1 hour after dose - no additional med
Use within 12 hours of reconstituting
References
(2005) Prescribers Letter 12(8):44
Dosing
Clarithromycin (Biaxin)
May take with or without food
Adult: 250 to 500 mg PO bid
Child: 7.5 mg/kg PO bid
Dosing
Telithromycin
Adult: 800 mg PO daily
Course
Acute Exacerbation of Chronic Bronchitis
: 5 days
Acute Sinusitis
: 5 days
Community Acquired Pneumonia
: 7 days
Adverse Effects
Class
Less
Nausea
and
Vomiting
than with
Erythromycin
QT Prolongation
(see below)
Three fold increased risk of
Sudden Cardiac Death
while on Azithromycin
Ray (2013) N Engl J Med 366(20): 1881-90 [PubMed]
Clarithromycin
Dysgeusia
or distorted taste (20%)
Calcium Channel Blocker
Drug Interaction
(see below)
Increased cardiovascular deaths
Observation in some studies as of 2018, but needs confirmation
Inghammer (2017) Am J Epidemiol +PMID:29155931 [PubMed]
Svanström (2014) BMJ 349:g4930 +PMID:25139799 [PubMed]
Drug Interactions
Clarithromycin
Calcium Channel Blocker
s
Clarithromycin increases
Calcium Channel Blocker
levels via
CYP3A4
inhibition
Highest risk with
Dihydropyridine Calcium Channel Blocker
s (
Nifedipine
, Felodipine)
Highest risk in age over 65 years old
Provokes
Hypotension
and
Bradycardia
Risk of
Acute Kidney Injury
(often requiring hospitalization)
Number needed to harm: 1 in 465 for over age 65 years
References
Gandhi (2013) JAMA 310(23):2544-53 [PubMed]
Indications
Major indications for broad spectrum
Macrolide
s
Single dose
Chlamydia trachomatis
treatment
Respiratory infections
Otitis Media
(Azithromycin)
Not recommended due to increased resistance rates
Community Acquired Pneumonia
Limit to suspected
Mycoplasma pneumonia
or
Legionella pneumonia
Macrolide
resistant pneumococcus is common
Consider
Doxycycline
as alternative
Acute Sinusitis
(Azithromycin)
Not recommended due to growing resistance rates
Streptococcal Pharyngitis
Macrolide
s are only indicated in significant allergy to beta-lactams
Non-tuberculous
Mycobacteria
l infections
Helicobacter
infections
References
(2013) Presc Lett 20(8): 44
Contraindications
Telithromycin (Ketek) may cause repiratory failure in
Myasthenia Gravis
(FDA Black Box Warning)
Preparations
Activity Spectrum
Macrolide
resistance is increasing
Resistance to one
Macrolide
is resistance to all
Spectrum includes organisms covered by
Erythromycin
Clarithromycin
Streptococcus Pneumoniae
(Pneumococcus)
Staphylococcus aureus
Toxoplasmosis
gondii
Mycobacterium leprae
Mycobacterium Avium Complex
Borrelia Burgdorferi
Azithromycin
Haemophilus
Influenza
e
Moraxella catarrhalis
Toxoplasmosis
gondii
Mycobacterium Avium Complex
(Clarithromycin better)
Borrelia Burgdorferi
Telithromycin
Avoid in patients with
Myasthenia Gravis
due to risk of
Respiratory Failure
(FDA Black Box Warning)
Similar to other Extended Spectrum Macrolides
Appears to have greater activity for pneumococcus
May be used in place of other broad spectrum agents
Augmentin
Extended spectrum
Fluoroquinolone
s
References
Fogarty (2003) J Antimicrob Chemother 51:947-55 [PubMed]
Type your search phrase here